Evidence mapPaperPMID 38553633Full record

ReviewNPJ precision oncology2024

Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment.

Sirvan Khalighi, Kartik Reddy, Abhishek Midya, Krunal Balvantbhai Pandav, Anant Madabhushi, Malak Abedalthagafi

Abstract readReview
In one paragraph

Review in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 5 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sirvan KhalighiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5563-1446
Kartik ReddyDepartment of Radiology, Emory University, Atlanta, GA, USA.
Abhishek MidyaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Krunal Balvantbhai PandavWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Anant MadabhushiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA. Anant.Madabhushi@emory.edu.ORCID http://orcid.org/0000-0002-5741-0399
Malak AbedalthagafiDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. Malak.althgafi@emory.edu.ORCID http://orcid.org/0000-0003-1786-3366

Funding

Project 4P50CA116201 · MAYO CLINIC ROCHESTER · 2005 to 2025
$4.7M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · 2022 to 2025
$1.2M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Vikas Gulani, Lee Evan Ponsky · 2022 to 2022
$582k
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI Pingfu Fu, Mark Lloyd · 2023 to 2023
$552k
Novel Radiomics for Predicting Response to Immunotherapy for Lung CancerR01CA257612 · EMORY UNIVERSITY · 2025 to 2025
$527k
BIOMEDICAL ENGINEERING RESEARCH FACILITIESC06RR012463 · CASE WESTERN RESERVE UNIVERSITY · 1997 to 1997
RadIO: A Novel Radiomics Toolkit to Predict and Characterize Response to Immunotherapy in Stage III Non-Small Cell Lung CancerI01BX004121 · VA · VETERANS HEALTH ADMINISTRATION · 2024 to 2025
BLRD VA I01 BX004121NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS R01 CA257612NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U54 CA254566NCRR NIH HHS C06 RR012463NIBIB NIH HHS R43 EB028736
6 · The paper itself

Abstract

This review delves into the most recent advancements in applying artificial intelligence (AI) within neuro-oncology, specifically emphasizing work on gliomas, a class of brain tumors that represent a significant global health issue. AI has brought transformative innovations to brain tumor management, utilizing imaging, histopathological, and genomic tools for efficient detection, categorization, outcome prediction, and treatment planning. Assessing its influence across all facets of malignant brain tumor management- diagnosis, prognosis, and therapy- AI models outperform human evaluations in terms of accuracy and specificity. Their ability to discern molecular aspects from imaging may reduce reliance on invasive diagnostics and may accelerate the time to molecular diagnoses. The review covers AI techniques, from classical machine learning to deep learning, highlighting current applications and challenges. Promising directions for future research include multimodal data integration, generative AI, large medical language models, precise tumor delineation and characterization, and addressing racial and gender disparities. Adaptive personalized treatment strategies are also emphasized for optimizing clinical outcomes. Ethical, legal, and social implications are discussed, advocating for transparency and fairness in AI integration for neuro-oncology and providing a holistic understanding of its transformative impact on patient care.

Identifiers

PMID38553633
PMCPMC10980741

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.